Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ihab G. Girgis"'
Autor:
Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He, Ihab G. Girgis, Anjaneya Chimalakonda, Bindu Murthy, Urvi Aras
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3153-3164 (2023)
Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and
Externí odkaz:
https://doaj.org/article/138681b5e9fe48568e696414c32c2790
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 1, Pp 151-164 (2023)
Abstract This randomized, double‐blind, single‐ and multiple‐ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small‐molecule inhibitor of tyrosine k
Externí odkaz:
https://doaj.org/article/160d05762f494727925f54c50e945cba
Publikováno v:
Clinical and Translational Science. 16:151-164
This randomized, double-blind, single- and multiple-ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small-molecule inhibitor of tyrosine kinase 2, in 100 (
Autor:
Anjaneya, Chimalakonda, Shalabh, Singhal, Raymond, Darbenzio, Randy, Dockens, David, Marchisin, Subhashis, Banerjee, Ihab G, Girgis, John, Throup, Bing, He, Urvi, Aras, Bindu, Murthy
Publikováno v:
Clinical Pharmacology in Drug Development. 11:442-453
Deucravacitinib is a novel, oral, selective inhibitor of the intracellular signaling kinase tyrosine kinase 2. This phase 1, randomized, partially double-blind, 4-period crossover study in healthy adults was conducted to determine whether deucravacit
Autor:
Kuan‐ju Lin, Shalabh Singhal, Shenita Basdeo, Huadong Sun, John Throup, Hannah Huang, Aberra Fura, Ang Liu, Sebastien Bihorel, Ihab G. Girgis, Elizabeth Ludwig, Diane E. Shevell, Jenny Xie, Santanu Dutta
Publikováno v:
Clinical Pharmacology in Drug Development
Sphingosine‐1‐phosphate (S1P) binding to the S1P‐1 receptor (S1P1R) controls the egress of lymphocytes from lymphoid organs and targets modulation of immune responses in autoimmune diseases. Pharmacologic modulation of S1P receptors has been li
Autor:
Dennis M. Grasela, Ihab G. Girgis, Ang Liu, Miroslawa Nowak, Bing He, Sudeep Kundu, Naiyu Zheng, Ian M. Catlett
Publikováno v:
British Journal of Clinical Pharmacology
Aims Branebrutinib (BMS-986195) is a potent, highly selective, oral, small-molecule, covalent inhibitor of Bruton's tyrosine kinase (BTK). This study evaluated safety, pharmacokinetics and pharmacodynamics of branebrutinib in healthy participants. Me
Autor:
Hongwei Zhang, Weiguo Cai, Ihab G. Girgis, Murli Krishna, Tarek A. Leil, John Throup, Huadong Sun, Leonid Gibiansky, Subhashis Banerjee, Huidong Gu
Publikováno v:
Clinical Pharmacology in Drug Development
BMS‐986184 is a human, second‐generation, anti–interferon‐γ–induced protein 10 (IP‐10) monoclonal antibody. In this study the pharmacokinetics and target engagement (TE) of BMS‐986184 in healthy participants were characterized using po
Autor:
June Ye, Ihab G. Girgis, Timothy E Albertson, Florian B. Mayr, Ian M. Catlett, Richard S. Hotchkiss, Mark Tidswell, Scott C. Brakenridge, Greg S. Martin, Lyle L. Moldawer, Michael W. Donnino, Raquel R. Bartz, Dennis M. Grasela, Pauline K. Park, Derek C. Angus, Craig M. Coopersmith, Matthew J. Delano, Elizabeth Colston, Elliott D. Crouser, Sachin Yende
Publikováno v:
Intensive Care Medicine. 45:1360-1371
Sepsis-associated immunosuppression increases hospital-acquired infection and viral reactivation risk. A key underlying mechanism is programmed cell death protein-1 (PD-1)-mediated T-cell function impairment. This is one of the first clinical safety
Autor:
Florian B. Mayr, Elizabeth Colston, Richard S. Hotchkiss, Craig M. Coopersmith, Greg S. Martin, Elliott D. Crouser, Lyle L. Moldawer, Scott C. Brakenridge, Ian M. Catlett, Dennis M. Grasela, Derek C. Angus, Ihab G. Girgis, Pauline K. Park, Sachin Yende, June Ye
Publikováno v:
Critical Care Medicine. 47:632-642
Objectives:To assess for the first time the safety and pharmacokinetics of an antiprogrammed cell death-ligand 1 immune checkpoint inhibitor (BMS-936559; Bristol-Myers Squibb, Princeton, NJ) and its effect on immune biomarkers in participants with se
Publikováno v:
Poster Presentations.
Background S1P mediates a number of immune processes including the egress of lymphocytes from lymphoid organs via stimulation of the S1P subtype 1 receptor (S1P1R). S1P1R inhibition has the potential to suppress abnormal immune responses and modulate